They already told you what happened in the 2nd Qtr. Nothing. Thats why they had to do a insider sale to Wexford and Evans to get 1.2M more cash.
Has anybody noticed how only Evans has received Stock Awards for being a BOD in December? Normally we see a Form 4 for every BOD member, yet in 2015 EOY all I see was Evans, and last time others got shares was in Sept. 2015. SOOOO, what does this mean? None of the other BOD did anything worth awarding them with shares?
Its now Q3. Can you provide a PR showing the preliminary Q2 revenue and expenses like has been done prior?
I just dont want to wait 45 days to see a report, i'm too impatient. I would like to know now if its bad and thats why funding was needed.
In the PR about closing the 1.2M note and warrant sale only made available to insiders and not us. Another fluff statement to try to alleviate the rage we are all feeling at this time. There are people on this MB who admittedly purchased through open market and stock sales over $100,000 worth, but are not good enough to get a phone call to be offered warrants. Why does Evans and Wexford need warrants? WHY? They already have millions and millions of shares/warrants, why in the world do they need more warrants? You're already getting an obscene 11% per annum return, and you need warrants too?
"We expect to see the initial revenue impact of our new products in the third quarter with significant growth through the end of this year," said Daron Evans, President and Chief Executive Officer of the Nephros. "We appreciate the continued support of our investors to provide working capital as we progress toward becoming a cash-flow positive company."
I am assuming that you are assuming that the Nephros filter is designed and cleared to filter Lead? Is it?
Can the Nephros filter survive metallic elements?
Ive been checking your website the past 2 months waiting to see if you're going to update it to show the new director of Business Development. Still no update.
No PR about his being hired either or what experience and skills he brings to the table. Does he have a long and distinguished career in BD in the medical devices field? How has he contributed to the companies bottom line since being brought on board?
Disagree with you Fred. If they sold today, it 'might' go for 10 cents a share. And why would they sell EOY when that would be when they claim to be CFP?
How about they make some money, get PPS up to $2 then solicit bids?
As is the nature of OTC stocks with no volume, if there ever was a day of significant news or developments, there most likely would be a substantial increase in PPS.
Whats intriguing in all of this is that Evans still says CFP this year. Well, based on the recent 1.2M fund raising and statement that significant revenue will be realised in Q3, then that tells me we will see a spike since Nephros will go from losing 500-600-800k a QTR to 0 or positive and that should pop it a little.
Most payment terms are NET 30 with contracts, some companies get away with NET 45 or NET 60 agreements, dont ask me how, and thats why it makes sense that Q3 would see the revenue from the Q4-Q1 products. What we then need though is to see Q4-2016 show an even greater increase over Q3 so that we know demand is actually organic and not just from a back-log.
I still hope Q2 #'s are about 800k product sales.
Camelbak owes Nephros a minimum monetary payment every year. Im sure its at least a decent #, maybe 100,000. Otherwise they lose the deal. My guess is they are fine tuning it to be able to push many many units and to market to many different countries. They wouldn't grab it to sit on it. They have a definite advantage by using the nephros tech.